Drug intelligence / Profile preview

BRY103

Development stage: Preclinical
Lead developer: Bryleos
Modality: Small Molecules
Administration: Oral

Overview

BRY103 is an investigational oral small molecule hormone being developed by Bryleos as a metabolic modulator. Utilizing Bryleos's proprietary LathMize platform, which is designed to enhance the stability and bioavailability of endogenous molecules, BRY103 acts as a metabolic rate regulator to modulate mitochondrial function. The candidate is currently in IND-enabling studies for the treatment of metabolic disorders, following a 505(b)(2) regulatory pathway.

Targets

THR (Thyroid hormone receptor)

Beyond the preview

Go deeper on BRY103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRY103.

Explore the full profile